

Wenjia Yang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7473138/publications.pdf>

Version: 2024-02-01

33
papers

818
citations

566801

15
h-index

525886

27
g-index

35
all docs

35
docs citations

35
times ranked

1357
citing authors

#	ARTICLE	IF	CITATIONS
1	Assessment of ovarian reserve in patients with type 1 diabetes: a systematic review and meta-analysis. <i>Endocrine</i> , 2022, 77, 205-212.	1.1	2
2	The association between the use of sodium glucose cotransporter 2 inhibitor and the risk of diabetic retinopathy and other eye disorders: a systematic review and meta-analysis. <i>Expert Review of Clinical Pharmacology</i> , 2022, 15, 877-886.	1.3	5
3	Dipeptidyl peptidase-4 inhibitor treatment and the risk of bullous pemphigoid and skin-related adverse events: A systematic review and meta-analysis of randomized controlled trials. <i>Diabetes/Metabolism Research and Reviews</i> , 2021, 37, e3391.	1.7	13
4	SGLT2 inhibitors and lower limb complications: an updated meta-analysis. <i>Cardiovascular Diabetology</i> , 2021, 20, 91.	2.7	32
5	Non-Insulin Antidiabetes Treatment in Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis. <i>Diabetes and Metabolism Journal</i> , 2021, 45, 312-325.	1.8	5
6	Cardiovascular outcomes of antidiabetes medications by race/ethnicity: A systematic review and meta-analysis. <i>Journal of Diabetes and Its Complications</i> , 2021, 35, 107980.	1.2	3
7	Denosumab or romosozumab therapy and risk of cardiovascular events in patients with primary osteoporosis: Systematic review and meta-analysis. <i>Bone</i> , 2020, 130, 115121.	1.4	71
8	The association between the biological disease-modifying anti-rheumatic drugs and the incidence of diabetes: A systematic review and meta-analysis. <i>Pharmacological Research</i> , 2020, 161, 105216.	3.1	8
9	Age, sex, disease severity, and disease duration difference in placebo response: implications from a meta-analysis of diabetes mellitus. <i>BMC Medicine</i> , 2020, 18, 322.	2.3	5
10	Glycemic control and the incidence of neoplasm in patients with type 2 diabetes: a meta-analysis of randomized controlled trials. <i>Endocrine</i> , 2020, 70, 232-242.	1.1	9
11	Serum Ratio of Free Triiodothyronine to Thyroid-Stimulating Hormone: A Novel Index for Distinguishing Graves' Disease From Autoimmune Thyroiditis. <i>Frontiers in Endocrinology</i> , 2020, 11, 620407.	1.5	2
12	The Body Weight Alteration and Incidence of Neoplasm in Patients With Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials. <i>Frontiers in Endocrinology</i> , 2020, 11, 541699.	1.5	4
13	Serum Albumin, but not Bilirubin, is Associated with Diabetic Chronic Vascular Complications in a Chinese Type 2 Diabetic Population. <i>Scientific Reports</i> , 2019, 9, 12086.	1.6	18
14	Cost-effectiveness analysis of dapagliflozin treatment versus metformin treatment in Chinese population with type 2 diabetes. <i>Journal of Medical Economics</i> , 2019, 22, 336-343.	1.0	19
15	A Decision-Support Software to Improve the Standard Care in Chinese Type 2 Diabetes. <i>Journal of Diabetes Research</i> , 2019, 2019, 1-6.	1.0	3
16	Associations between metformin use and vitamin B ₁₂ levels, anemia, and neuropathy in patients with diabetes: a meta-analysis. <i>Journal of Diabetes</i> , 2019, 11, 729-743.	0.8	61
17	Meta-analysis and critical review on the efficacy and safety of alpha-glucosidase inhibitors in Asian and non-Asian populations. <i>Journal of Diabetes Investigation</i> , 2018, 9, 321-331.	1.1	43
18	Addition of dipeptidyl peptidase-4 inhibitors to insulin treatment in type 2 diabetes patients: A meta-analysis. <i>Journal of Diabetes Investigation</i> , 2018, 9, 813-821.	1.1	19

#	ARTICLE	IF	CITATIONS
19	No disparity of the efficacy and all-cause mortality between Asian and non-Asian type 2 diabetes patients with sodium-glucose cotransporter 2 inhibitors treatment: A meta-analysis. <i>Journal of Diabetes Investigation</i> , 2018, 9, 850-861.	1.1	49
20	The Association Between the Dosage of SGLT2 Inhibitor and Weight Reduction in Type 2 Diabetes Patients: A Meta-Analysis. <i>Obesity</i> , 2018, 26, 70-80.	1.5	109
21	Efficacy and Safety of Initial Combination Therapy in Treatment-Naïve Type 2 Diabetes Patients: A Systematic Review and Meta-analysis. <i>Diabetes Therapy</i> , 2018, 9, 1995-2014.	1.2	28
22	Disparities in the Efficacy of Metformin in Combination with Dipeptidyl Peptidase-4 Inhibitor as Initial Treatment Stratified by Dosage and Ethnicity: A Meta-Analysis. <i>Diabetes Technology and Therapeutics</i> , 2018, 20, 704-714.	2.4	2
23	The association of smoking and risk of diabetic retinopathy in patients with type 1 and type 2 diabetes: a meta-analysis. <i>Endocrine</i> , 2018, 62, 299-306.	1.1	65
24	Comparisons of weight changes between sodium-glucose cotransporter 2 inhibitors treatment and glucagon-like peptide-1 analogs treatment in type 2 diabetes patients: A meta-analysis. <i>Journal of Diabetes Investigation</i> , 2017, 8, 510-517.	1.1	51
25	Relationship Between Gestational Weight Gain and Pregnancy Complications or Delivery Outcome. <i>Scientific Reports</i> , 2017, 7, 12531.	1.6	38
26	Comparison between insulin degludec/liraglutide treatment and insulin glargine/lixisenatide treatment in type 2 diabetes: a systematic review and meta-analysis. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 1789-1798.	0.9	26
27	The Magnitude of Weight Loss Induced by Metformin is Independently Associated with BMI at Baseline in Newly Diagnosed Type 2 Diabetes: Post-hoc Analysis from Data of a Phase IV Open-labeled Trial. <i>Advances in Clinical and Experimental Medicine</i> , 2017, 26, 671-677.	0.6	4
28	DPP-4 Inhibitor Treatment in Chinese Type 2 Diabetes Patients: A Meta-Analysis. <i>Diabetes Technology and Therapeutics</i> , 2016, 18, 784-793.	2.4	14
29	DPP-4 inhibitors and risk of infections: a meta-analysis of randomized controlled trials. <i>Diabetes/Metabolism Research and Reviews</i> , 2016, 32, 391-404.	1.7	54
30	Efficacy of hypoglycemic treatment in type 2 diabetes stratified by age or diagnosed age: a meta-analysis. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 1591-1598.	0.9	2
31	Clinical Characteristics of Young Type 2 Diabetes Patients with Atherosclerosis. <i>PLoS ONE</i> , 2016, 11, e0159055.	1.1	12
32	Baseline Body Mass Index and the Efficacy of Hypoglycemic Treatment in Type 2 Diabetes: A Meta-Analysis. <i>PLoS ONE</i> , 2016, 11, e0166625.	1.1	21
33	Comparisons of the efficacy of glucose control, lipid profile, and β -cell function between DPP-4 inhibitors and AGI treatment in type 2 diabetes patients: a meta-analysis. <i>Endocrine</i> , 2015, 50, 590-597.	1.1	19